Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
accessible, adjunctive, affordability, aGVHD, Alzheimer, antipsychotic, approach, arena, Argentine, Augtyro, Barcelona, Belgium, BICR, Biden, biopharmaceutical, borrowing, bridge, Bruton, calcineurin, cap, cetuximab, CGDP, checkpoint, choice, cisplatin, CODM, colorectal, communicated, compound, conjugate, Crohn, deficient, dermatology, detail, devaluation, differentiated, displayed, diversification, doubled, dual, efficiency, Empliciti, epidemic, evidence, experience, expiry, fall, faster, fee, fiscal, focused, focusing, framework, gastroenteropancreatic, gastrointestinal, gemcitabine, gene, greatest, growing, harboring, IMDC, immunotherapy, inflation, intermediate, Intermountain, invasive, IO, jointly, Karuna, KarXT, lack, Legacy, lenvatinib, lifted, loan, Madrid, Mainland, mCRC, mechanism, medicine, member, metabolic, methotrexate, microsatellite, mismatch, morbidity, muscle, necessarily, neuroendocrine, neuroinflammation, neurological, neuropsychiatry, Norman, NTRK, Nulojix, OECD, opposition, optimizing, passed, peso, PFS, Pillar, pivotal, pooled, post, potent, predict, pretreated, professional, prognostic, psychiatric, pulmonology, radiopharmaceutical, rapidly, RayzeBio, rebound, recast, reinvested, release, released, repair, replacing, rest, retrospective, rheumatology, Romania, RPT, scalable, schizophrenia, side, SLL, solid, sorafenib, stability, SystImmune, thrombotic, tied, tolerability, tolling, topoisomerase, turnaround, ulcerative, valuation, YELLOWSTONE
Removed:
acquiree, arbitration, ASR, assessing, assigning, AZ, azacitidine, back, BCBSA, begin, BeiGene, bowel, breach, Chamber, chemoimmunotherapy, Cheplapharm, collaborate, Commerce, Commonwealth, consulting, Corrupt, count, creditable, curative, decided, declaratory, decline, decree, defense, demonstrating, dependent, discontinue, DNA, Dragonfly, duration, eligible, elimination, enabled, enhanced, equally, escrow, execution, fedratinib, funding, geographical, HPI, hypomethylating, identified, IIB, IIC, Imfinzi, Imjudo, incomplete, inconsistency, incur, inflammatory, Influenced, institute, intensive, inter, jury, Kingdom, lapse, Letter, LOE, lost, LP, LSA, measurement, measuring, misrepresentation, MyoKardia, negligent, NJ, OTC, Pharmacy, Pike, psoriatic, Racketeer, rank, reach, recognize, redeemable, redemption, regular, relevant, repurchased, resected, restriction, returned, returning, reverted, ring, RNA, sheet, shutdown, studied, sustain, TCR, terminating, thrombocythemia, transfusion, treasury, unit, unpaid, upcoming, vacate, varying, vera, verdict, Vidaza
Financial report summary
?Competition
Perspective Therapeutics • Geovax Labs • Mosaic ImmunoEngineering • Delcath Systems • Lineage Cell Therapeutics • Geron • Tapestry Pharmaceuticals • Sangamo Therapeutics • TG Therapeutics • Inovio PharmaceuticalsManagement Discussion
- (a) Other revenues include royalties and alliance-related revenues for products not sold by our regional commercial organizations.
- (b) Foreign exchange impacts were derived by applying the prior period average currency rates to the current period sales.
- •U.S. revenues increased 7% during the first quarter of 2024 primarily due to higher demand for Growth and Legacy Portfolio products, partially offset by lower average net selling prices for the Legacy Portfolio. Average U.S. net selling prices decreased 1% compared to the same period a year ago.